Infliximab (Remicade) is the Innovator/Original – Welcome Biosimilar(s)
There has been an enormous amount of focus by many pharmaceutical and biotech companies in the past several years to figure out how to bring biosimilars to the hands (or doctors’ hands), specifically with regards to people with ulcerative colitis and other immune system related diseases.
The question that many people have, doctors, nurses, and especially patients and concerned family members is….
Do they work, and are they safe?
I am very interested to find out how people who use this website are doing if they have been using any of the biosimilars.
Some questions I have are:
- How did your doctor explain the new medication to you?
- Were you pressured by your insurance company to begin using the biosimilar for cost reasons?
- Did you notice anything different? (positive/negative)
- How have the results been?
- Anything else you would like to add..?
Here are a few headlines/stories and their links that might be interesting for you:
- Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
- Biosimilar infliximab use in paediatric IBD
- Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Thanks again for taking a few moments to check out some of this info, for sure there are many many UC’ers who are taking biologics to treat UC, and I’m hoping that before too long, we will have some feedback from either some folks who were involved with the clinical trials and/or feedback from people who began using the biosimilars once they were authorized for use. As some of the authorizations for its use as a marketed product are different in different countries, there is definite potential that in your particular country something is not yet available, however it may be another country…(seems to be just how it works).
Thanks for reading,